U.S. Markets closed

Ipsen S.A. (IPN.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
110.05+0.55 (+0.50%)
At close: 5:35PM CEST

Ipsen S.A.

65, quai Georges Gorse
Cedex
Boulogne-Billancourt 92650
France
33 1 58 33 50 00
http://www.ipsen.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees5,100

Key Executives

NameTitlePayExercisedAge
Mr. David D. MeekChief Exec. Officer and Director1.6MN/A53
Mr. Aymeric Le ChatelierExec. VP of Fin.N/AN/A48
Dr. Alexandre P. LeBeaut M.D.Chief Scientific Officer and Exec. Vice-Pres of R&DN/AN/A60
Mr. Pierre KemulaVP of Corp. Fin., Treasury and Financial MarketsN/AN/AN/A
Ms. Eugenia LitzVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Primary Care and Specialty Care. The company offers drugs in urology – oncology, endocrinology, neurology, gastroenterology, cognitive disorders, rheumatology, and cardiovascular areas. Its products include Decapeptyl, a synthetic hormone made of triptorelin and decapeptide analog of gonadotrophin releasing hormone, for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; Hexvix, a photosensitizing agent, for detection and resection of non invasive bladder cancer; and Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum toxin type A complex used to treat cervical dystonia, cerebral palsy, blepharospasms, and hemifacial spasms. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan for the treatment of age-related cognitive disorders. Further, the company provides Nisis and Nisisco, which are antihypertensive agents for treating hypertension; Adenuric for the treatment of gout; and Adrovance for treating post-menopausal osteoporosis. Additionally, it is developing chimeric somastatin and dopamine agonist molecule, BN82451, VSN16R, OPS201, OPS202, MCNA, and LX1032 drugs. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Corporate Governance

Ipsen S.A.’s ISS Governance QualityScore as of August 1, 2017 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.